Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP9X | Q93008 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
| ▸ | VNN1 | O95497 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31284966 | 0.87 | EED (0.34) | ENPP2 | |
| SCHEMBL31285042 | 0.78 | — | — | |
| SCHEMBL31285640 | 0.78 | ENPP2 (0.37) | ENPP2 | |
| SCHEMBL12510465 | 0.77 | CYP11B1 (0.33) | ENPP2PTGS2 | |
| SCHEMBL3755263 | 0.77 | CYP2C19 (0.43) | KDM4EENPP2PTGS2 | |
| SCHEMBL31359426 | 0.77 | CYP2C19 (0.43) | KDM4EENPP2PTGS2 | |
| SCHEMBL31285054 | 0.76 | NR3C1 (0.40) | ENPP2 | |
| SCHEMBL3416281 | 0.76 | TP53 (0.33) | ENPP2PTGS2VNN1 | |
| SCHEMBL3418683 | 0.76 | KCNN4 (0.40) | ENPP2PTGS2 | |
| SCHEMBL34464541 | 0.76 | ENPP2 (0.36) | ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101052638-B | As α24- (condensed cyclomethyl) -imidazole-2-thiones as adrenergic agonists | ALLERGAN INC | 2011-01-19 | — | — | CN | disclosed |
| US-7838545-B2 | 4-(condensed cyclicmethyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists | ALLERGAN, INC. (US) | 2010-11-23 | — | — | US | disclosed |
| US-20090176828-A1 | 4-(CONDENSED CYCLICMETHYL)-IMIDAZOLE-2-THIONES ACTING AS ALPHA2 ADRENERGIC AGONISTS | ALLERGAN, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-7396849-B2 | 4-(Condensed cyclicmethyl)-imidazole-2-thiones acting as α2 adrenergic agonists | ALLERGAN, INC. (US) | 2008-07-08 | — | — | US | disclosed |
| CN-101052638-A | As α24- (condensed cyclomethyl) adrenergic agonists-imidazole-2-thiones | ALLERGAN INC (US) | 2007-10-10 | — | — | CN | disclosed |
| EP-1791833-A2 | 4-(CONDENSED CYCLICMETHYL)-IMIDAZOLE-2-THIONES ACTING AS ALPHA2 ADRENERGIC AGONISTS | Allergan, Inc. (US) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006036497-A2 | 4-(CONDENSED CYCLICMETHYL)-IMIDAZOLE-2-THIONES ACTING AS ALPHA2 ADRENERGIC AGONISTS | ALLERGAN, INC. (US) | 2006-04-06 | — | — | WO | disclosed |
| US-20060069144-A1 | 4-(Condensed cyclicmethyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists | ALLERGAN, INC. | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069144-A1 | 4-(Condensed cyclicmethyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists | ADRB2, ADRA2C, ADRA2A | USP9X 4695/4885KDM4E 2607/4885ENPP2 2744/4885 |
| US-20090176828-A1 | 4-(CONDENSED CYCLICMETHYL)-IMIDAZOLE-2-THIONES ACTING AS ALPHA2 ADRENERGIC AGONISTS | ADRB2, ADRA2C, ADRA2A | USP9X 4610/4885KDM4E 3132/4885ENPP2 2804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.